Program
Cetuximab
Also written as “cetuximab”, “RPH-002” and “Cetuximab + Irinotecan”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Neoplasms, led by 26 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 300 open or running | phase 3since Jun 4, 2003 | Apr 30, 2002 | none ahead |
| Merck KGaA, Darmstadt, Germany | 170 open or running | phase 3since Sep 7, 2005 | Jul 28, 2005 | none ahead |
| Pfizer | 53 open or running | phase 3since Oct 5, 2020 | Dec 1, 2010 | Dec 31, 2029phase 2 · NCT05226871 |
| Bristol-Myers Squibb | 40 open or running | phase 3since Nov 17, 2017 | Jan 7, 2008 | none ahead |
| Hoffmann-La Roche | 41 open or running | phase 2since Dec 18, 2007 | Jul 3, 2007 | Aug 31, 2030phase 1 · NCT04929223 |
| R-Pharm | 40 open or running | phase 3since Feb 20, 2026 | Sep 28, 2006 | none ahead |
| Sarah Cannon Research Institute | 41 open or running | phase 3since Nov 9, 2005 | Nov 2, 2005 | none ahead |
| Merck | 22 open or running | phase 3since May 21, 2025 | May 21, 2025 | Mar 28, 2029phase 3 · NCT06997497 |
| Novartis | 20 open or running | phase 2since May 16, 2012 | May 24, 2007 | none ahead |
| Pierre Fabre | 20 open or running | phase 2since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| Bayer | 10 open or running | phase 1since Oct 28, 2013 | Oct 28, 2013 | none ahead |
| BOE Technology Group | 11 open or running | phase 2since Apr 10, 2026 | Apr 10, 2026 | Apr 2028phase 2 · NCT07551778 |
| Boehringer Ingelheim | 10 open or running | phase 1since Dec 19, 2013 | Dec 19, 2013 | none ahead |
| boneca-corporation | 10 open or running | phase 2since Jun 21, 2009 | Jun 21, 2009 | none ahead |
| cinnagen | 11 open or running | phase 3since Dec 31, 2017 | Dec 31, 2017 | none ahead |
| Daiichi Sankyo | 10 open or running | phase 1since Jan 19, 2015 | Jan 19, 2015 | none ahead |
| Fosun Pharma | 11 open or running | phase 1since Apr 7, 2026 | Apr 7, 2026 | Jun 30, 2027phase 1 · NCT07543471 |
| GlaxoSmithKline | 10 open or running | phase 1since Oct 5, 2007 | Oct 5, 2007 | none ahead |
| Haisco Pharmaceutical Group | 11 open or running | phase 2since Aug 13, 2026 | Aug 13, 2026 | Sep 30, 2029phase 2 · NCT07790510 |
| harrison-clinical-research | 10 open or running | phase 1since Jan 9, 2009 | Jan 9, 2009 | none ahead |
| innate-pharma | 10 open or running | phase 2since Dec 17, 2015 | Dec 17, 2015 | none ahead |
| integragen-sa | 10 open or running | phase 3since Nov 24, 2017 | Nov 24, 2017 | none ahead |
| Merrimack Pharmaceuticals | 10 open or running | phase 1since Oct 7, 2011 | Oct 7, 2011 | none ahead |
| Revolution Medicines | 11 open or running | phase 2since May 20, 2024 | May 20, 2024 | Sep 30, 2028phase 2 · NCT06445062 |
| shanghai-celfuture-biotech-co-ltd | 10 open or running | phase 2since Jan 4, 2023 | Jan 4, 2023 | none ahead |
| Verastem | 11 open or running | phase 2since Jun 15, 2026 | Jun 15, 2026 | Jun 2027phase 2 · NCT07659795 |
Also a collaborator on its studies: Ono Pharmaceutical, AstraZeneca, prologue-research-international, Sanofi and merck-s-l-spain.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jul 3, 2007.
- Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
- Apr 30, 2021Phase 2 study in Colorectal NeoplasmsPierre Fabre · NCT05004350 · 107 enrolled · China
- Jun 11, 2021Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT04929223 · 542 planned · United States, Australia, Canada and more
- Jan 19, 20222 phase 2 studiesPfizer · NCT05217446, NCT05226871
- Jan 4, 2023shanghai-celfuture-biotech-co-ltd's first study: phase 2 study in Colorectal NeoplasmsNew to shanghai-celfuture-biotech-co-ltdshanghai-celfuture-biotech-co-ltd · NCT05684211 · 84 enrolled · China
- May 20, 2024Revolution Medicines's first study: phase 2 study in Colorectal NeoplasmsNew to Revolution MedicinesRevolution Medicines · NCT06445062 · 1,130 planned · United States
- May 21, 2025Merck's first study: phase 3 study in Colonic NeoplasmsNew to MerckMerck · NCT06997497 · 477 planned · United States, Argentina, Australia and more
- Nov 20, 2025Phase 2 study in NeoplasmsMerck · NCT07252739 · 140 planned · United States, Chile, China and more
- Feb 20, 2026Phase 3 study in Squamous Cell Carcinoma of Head and NeckPhase 3 reachedR-Pharm · NCT07435324 · 161 enrolled · Russia, Uzbekistan
- Feb 20, 2026Phase 1 study in Squamous Cell Carcinoma of Head and NeckR-Pharm · NCT07435311 · 118 enrolled · Russia
- Apr 7, 2026Fosun Pharma's first study: phase 1 study in mCRCNew to Fosun PharmaFosun Pharma · NCT07543471 · 387 planned
- Apr 10, 2026BOE Technology Group's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to BOE Technology GroupBOE Technology Group · NCT07551778 · 42 planned
- Jun 15, 2026Verastem's first study: phase 2 study in Colorectal NeoplasmsNew to VerastemVerastem · NCT07659795 · 150 planned · United States, Australia
- Aug 13, 2026Haisco Pharmaceutical Group's first study: phase 2 study in Colorectal NeoplasmsNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT07790510 · 180 planned · China
Ahead
- Jun 2027Primary completion: phase 2 study in Colorectal NeoplasmsVerastem · NCT07659795
- Jun 30, 2027Primary completion: phase 1 study in mCRCFosun Pharma · NCT07543471
- Apr 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBOE Technology Group · NCT07551778
- Sep 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsRevolution Medicines · NCT06445062
TargetBeta
“A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
The newest 60 of 90 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07790510Colorectal Neoplasms · China | 2 | Recruiting | Haisco Pharmaceutical Group | Sep 30, 2029 | 180 |
| NCT07659795Colorectal Neoplasms · United States, Australia | 2 | Recruiting | Verastem | Jun 2027 | 150 |
| NCT07551778Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | BOE Technology Group | Apr 2028 | 42 |
| NCT07543471mCRC | 1 | Not yet recruiting | Fosun Pharma | Jun 30, 2027 | 387 |
| NCT07435324Squamous Cell Carcinoma of Head and Neck · Russia, Uzbekistan | 3 | Completed | R-Pharm | Sep 16, 2025 | 161 |
| NCT07435311Squamous Cell Carcinoma of Head and Neck · Russia | 1 | Completed | R-Pharm | Jul 17, 2024 | 118 |
| NCT07252739Neoplasms · United States, Chile, China and more | 2 | Recruiting | Merck | Nov 15, 2029 | 140 |
| NCT06997497Colonic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Mar 28, 2029 | 477 |
| NCT06445062Colorectal Neoplasms · United States | 2 | Recruiting | Revolution Medicines | Sep 30, 2028 | 1,130 |
| NCT05684211Colorectal Neoplasms · China | 2 | UNKNOWN | shanghai-celfuture-biotech-co-ltd | Jan 2023 | 84 |
| NCT05226871Breast Neoplasms · United States, China, Mexico and more | 2 | Active, not recruiting | Pfizer | Dec 31, 2029 | 35 |
| NCT05217446Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | Pfizer | Jun 19, 2026 | 108 |
| NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Hoffmann-La Roche | Aug 31, 2030 | 542 |
| NCT05004350Colorectal Neoplasms · China | 2 | Completed | Pierre Fabre | Dec 19, 2023 | 107 |
| NCT04607421Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Mar 1, 2025 | 841 |
| NCT04515394Colorectal Neoplasms · United States, Belgium, Czechia and more | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Mar 14, 2022 | 3 |
| NCT03717155Carcinoma, Non-Small-Cell Lung · Hungary, Serbia, Spain | 2 | Completed | Merck KGaA, Darmstadt, Germany | Sep 30, 2020 | 43 |
| NCT03693170Colorectal Neoplasms · United States, Austria, Belgium and more | 2 | Completed | Pierre Fabre | Jun 29, 2020 | 95 |
| NCT03391934Colorectal Neoplasms · Iran, Islamic Republic of | 3 | Recruiting | cinnagen | Nov 30, 2025 | 234 |
| NCT03362684Colorectal Neoplasms | 3 | Completed | integragen-sa | Nov 2009 | 1,808 |
| NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more | 3 | Completed | Bristol-Myers Squibb | Oct 14, 2019 | 74 |
| NCT02643550Head and Neck Neoplasms · United States, France | 2 | Completed | innate-pharma | Mar 28, 2023 | 143 |
| NCT02383966Squamous Cell Carcinoma of Head and Neck · Germany | 3 | Completed | Merck KGaA, Darmstadt, Germany | Jan 19, 2018 | 243 |
| NCT02350712Squamous Cell Carcinoma of Head and Neck · United Kingdom | 1 | Completed | Daiichi Sankyo | Mar 2016 | 15 |
| NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more | 2 | Completed | Hoffmann-La Roche | May 31, 2019 | 1,044 |
| NCT02124850Squamous Cell Carcinoma of Head and Neck · United States | 1 | Terminated | Bristol-Myers Squibb | Aug 11, 2016 | 18 |
| NCT02020577Neoplasms · France, Spain | 1 | Completed | Boehringer Ingelheim | Jan 2015 | 58 |
| NCT01973868Neoplasms · United States | 1 | Completed | Bayer | Jan 31, 2017 | 42 |
| NCT01719380Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Oct 31, 2015 | 156 |
| NCT01602315Squamous Cell Carcinoma of Head and Neck · United States, Australia, Canada and more | 2 | Terminated | Novartis | Sep 16, 2016 | 179 |
| NCT01451632Colorectal Neoplasms · United States | 1 | Completed | Merrimack Pharmaceuticals | Nov 2013 | 48 |
| NCT01450319Colorectal Neoplasms · Spain | 2 | Completed | Merck KGaA, Darmstadt, Germany | Dec 2014 | 73 |
| NCT01388790Stomach Neoplasms · Germany | 2 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2012 | 40 |
| NCT01252628Recurrence · United States, Canada | 2 | Completed | Pfizer | Nov 2013 | 178 |
| NCT01228734Colorectal Neoplasms · China | 3 | Completed | Merck KGaA, Darmstadt, Germany | Jan 25, 2016 | 553 |
| NCT01177956Squamous Cell Carcinoma of Head and Neck · China, Korea, Republic of | 3 | Completed | Merck KGaA, Darmstadt, Germany | Jan 2011 | 73 |
| NCT01109524Lung Neoplasms · United States, Canada, Puerto Rico | 2 | Completed | Eli Lilly | Sep 2012 | 72 |
| NCT01099358Head and Neck Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | Oct 2015 | 47 |
| NCT01087970Head and Neck Neoplasms · United States | 2 | Completed | Eli Lilly | Aug 2013 | 69 |
| NCT01086267Colorectal Neoplasms · United States, Canada | 2 | Completed | Bristol-Myers Squibb | Aug 2011 | 17 |
| NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico | 2 | Completed | Eli Lilly | Aug 2013 | 187 |
| NCT01063075Head and Neck Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | May 2015 | 34 |
| NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more | 2 | Completed | Eli Lilly | Feb 2012 | 66 |
| NCT01012258Squamous Cell Carcinoma of Head and Neck · China | 3 | Completed | Merck KGaA, Darmstadt, Germany | Sep 2010 | 70 |
| NCT00971932Squamous Cell Carcinoma of Head and Neck · Japan | 2 | Completed | Merck KGaA, Darmstadt, Germany | Mar 2011 | 33 |
| NCT00927147Head and Neck Neoplasms · Finland | 2 | Terminated | boneca-corporation | Jun 2013 | 17 |
| NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more | 2 | Completed | Eli Lilly | May 2011 | 113 |
| NCT00865098Carcinoma of the Head and Neck · Japan | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jun 2010 | 27 |
| NCT00820755Carcinoma, Non-Small-Cell Lung · Germany | 3 | Completed | Merck KGaA, Darmstadt, Germany | Dec 2011 | 583 |
| NCT00820417Colorectal Neoplasms · Belgium, Spain | 1 | Completed | harrison-clinical-research | Sep 2007 | 63 |
| NCT00768131Lung Neoplasms · United States | 2 | Withdrawn | Eli Lilly | Oct 2008 | 0 |
| NCT00698841Advanced Cancer · United States, Puerto Rico | 2 | Completed | Eli Lilly | Feb 2010 | 79 |
| NCT00678535Stomach Neoplasms · Argentina, Australia, Austria and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Mar 2012 | 904 |
| NCT00633464Breast Neoplasms · Austria, Czech Republic, France and more | 2 | Completed | R-Pharm | Sep 2010 | 79 |
| NCT00594984Colorectal Neoplasms · United States, Argentina, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Dec 2012 | 38 |
| NCT00577109Colorectal Neoplasms · Brazil | 2 | Withdrawn | Hoffmann-La Roche | Jun 2012 | 0 |
| NCT00540943Colorectal Neoplasms · France | 1 | Completed | GlaxoSmithKline | May 3, 2010 | 25 |
| NCT00527111Rectal Neoplasms · United States | 2 | Completed | Sarah Cannon Research Institute | Jan 2015 | 139 |
| NCT00517829Gastric Cancer Adenocarcinoma Metastatic · United States | 2 | Completed | Sarah Cannon Research Institute | Apr 2012 | 150 |
| NCT00497497Colorectal Neoplasms | 1 | Completed | Hoffmann-La Roche | Sep 2010 | 20 |
How it is read
Names in the registry
- “Cetuximab”, 57 entries
- “cetuximab”, 11 entries
- “RPH-002”, 2 entries
- “Cetuximab + Irinotecan”, 2 entries
- “Cetuximab + mFOLFOX6”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 34 studies
- Carcinoma, Non-Small-Cell Lung, 17 studies
- Squamous Cell Carcinoma of Head and Neck, 10 studies
- Head and Neck Neoplasms, 7 studies
- Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.